Office for Technology Commercialization

S100A4 inhibitor “Minnetamide” for prostate cancer treatment

Technology #2020-242

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
University of Minnesota, Technology Commercialization
Mohammad Saleem Bhat, PhD
Associate Professor, Dept. of Urology
External Link (
Managed By
Kenneth Karanja
Technology Licensing Officer 612-624-4531
Patent Protection

Provisional Patent Application Filed


  • Prostate cancer treatment

Technology Overview

Current treatments for prostate cancers (PC) are highly variable in their efficacy, particularly in the case of aggressive forms of cancers such as neuroendocrine type PC (NEPC). The technology is a small molecule (called “S100A-Minnetamide”) that inhibits a novel drug target, S100 calcium-binding protein A4 (S100A4). In animal models of disease, S100A-Minnetamide is well tolerated, bioavailable and results in reduced cancer growth

Phase of Development

In vitro and in vivo/animal studies completed.

Desired Partnerships

This technology is now available for:

  • License
  • Sponsored research
  • Co-development
Please contact Kenneth Karanja to share your business’ needs and learn more.